Navigation Links
Novira Therapeutics Expands Management Team with Appointment of Klaus Klumpp, Ph.D., the Former Global Head of Roche's Virology Discovery Initiatives, as Vice President Discovery Research
Date:6/5/2013

DOYLESTOWN, Pa., June 5, 2013 /PRNewswire/ -- Novira Therapeutics Inc., today announced the expansion of its senior management team with the appointment of Klaus Klumpp , Ph.D., as vice president, discovery research. Dr. Klumpp will build an internal virology team focused on the hepatitis B virus (HBV) and will oversee biology research at Novira.

"The addition of Klaus is an important step in the growth of our company as we transition from a discovery stage company into a development stage company," said Osvaldo Flores , Ph.D., president and chief scientific officer of Novira. "We are excited to welcome Klaus to our team. His expertise and outstanding record of accomplishments in antiviral drug discovery and clinical development further strengthen Novira's capabilities. Dr. Klumpp will be instrumental in our efforts to build a world class virology team, develop powerful tools to characterize mechanisms of HBV persistence and to develop innovative drugs that can cure chronic HBV infection."

Prior to joining Novira, Dr. Klumpp led research and development activities for more than 15 years at Roche, including leadership of teams at the company's locations in Welwyn Garden City, U.K., Palo Alto, Calif., and most recently Nutley, N.J. At the New Jersey site, he was vice president and global head of virology discovery.

Dr. Klumpp has an established track record of successful research and development activities that has involved collaborations with other companies and academic laboratories. He was responsible for the discovery and transition into clinical development of a number of new leads and drug candidates for the treatment of acute and chronic viral diseases, including influenza, hepatitis C, HBV, Dengue and HIV. In addition, he supported the clinical development of antiviral drugs such as Tamiflu for the treatment and prophylaxis of influenza virus infection and Balapiravir, Mericitabine and Danoprevir, new antiviral agents for the treatment of HCV infection.

Dr. Klumpp received a doctorate in virology from work performed at the Wellcome Research Laboratories, Beckenham, Kent, U.K ., at the European Molecular Biology Laboratories (EMBL), Heidelberg, Germany, and  at the EMBL in Grenoble, France. He holds a diploma degree in biology from the Technical University Darmstadt, Germany.

About Novira Therapeutics
Novira Therapeutics is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV infection, a global disease with a high level of unmet medical need. Novira's oral drugs target the core protein of the virus and offer a promising treatment option both as monotherapy and in combination with current standards of care. The company's antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors, is rarely curative despite lifelong treatment.

For more information, visit www.noviratherapeutics.com.

Contacts:

Corporate Contact
Osvaldo Flores , Ph.D.
President, CSO
lflores@noviratherapeutics.com

Media Contacts
David Schull                      
Matt Middleman, M.D.                                 
Russo Partners                                        
T: 212-845-4271                              
T: (212) 845-4272
david.schull@russopartnersllc.com
matt.middleman@russopartnersllc.com


'/>"/>
SOURCE Novira Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Nov. 29, 2016 Several leading ... by Accera, Inc. at 11 a.m. EST ... International Conference on Clinical Trials for Alzheimer,s Disease (CTAD). ... metabolism in Alzheimer,s disease and therapeutic targets that address ... "Following the recent failure of another therapy targeting ...
(Date:12/5/2016)... DUBLIN , Dec 5, 2016 ... Blotting Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, ... Companies) - Global Forecasts to 2021" report to their offering. ... , , ... reach USD 730.7 Million in 2021 from USD 574.8 Million in ...
(Date:12/5/2016)... and PUNE, India , December 5, 2016 /PRNewswire/ ... titled, "Surgical Sutures Market by Product Type and by Application - Global Opportunity ... for $3,360 million in 2015, and is expected to reach $5,255 million by ... segment dominated the market in 2015 with more than four-fifths share. ... ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... 2016 , ... Just in time for the holiday season, the celebrated paleo ... for Honeyville’s new Organic Quinoa Flour product for sale at Costco stores throughout the ... , “I think it’s wonderful that a growing number of retailers such as ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement ... of the world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... of a powerful woman's story of sacrifice and enlightenment. , “Tatiana ... author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing through ...
(Date:12/6/2016)... ... December 06, 2016 , ... The OSHA Training Center ... Education Center headquartered in Northern California, has announced the addition of a Public ... health training to public sector employees. , “The primary goal of the Public ...
(Date:12/5/2016)... ... 05, 2016 , ... What: Shriners Hospitals for Children, with the help of ... – using a video monitor and web-enabled camera. Santa visits with children through Dimension ... a Christmas Wonderland, which is where the video connection to the North Pole will ...
Breaking Medicine News(10 mins):